70-year-old-woman with extremely dense breasts

70-year-old-woman with extremely dense breasts. A. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from baseline AB-MR examination is negative (BI-RADS category 1). B. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from subsequent-round AB-MR examination performed 2 years later shows new 5-mm enhancing mass in upper outer right breast (arrow), which was not seen on mammogram performed 5 months prior. Examination was assessed as BI-RADS category 5. Ultrasound-guided core biopsy yielded invasive ductal carcinoma (ER+/PR+/HER2-).


June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower abnormal interpretation rate (AIR) compared to baseline examinations, while maintaining high cancer detection rate (CDR), according to the American Journal of Roentgenology (AJR).

Pointing out that all cancers detected by subsequent-round examinations were early-stage node-negative cancers, “further investigations are warranted to optimize the screening interval,” noted first author Christine E. Edmonds, MD, from the Hospital of the University of Pennsylvania. “The findings support sequential AB-MR for supplemental screening in individuals with dense breasts.”

AJR Editor in Chief Andrew Rosenkrantz, MD, speaks with Dr. Edmonds about her study comparing outcomes between baseline and subsequent rounds of screening abbreviated breast MRI in individuals with dense breasts.

Edmonds et al.’s AJR accepted manuscript included patients with dense breasts, at otherwise average breast-cancer risk, who underwent AB-MR for supplemental screening between December 20, 2016 and May 10, 2023. After extracting clinical interpretations and results of recommended biopsies for AB-MR examinations from the EMR, the researchers compared baseline and subsequent-round AB-MR examinations.

Ultimately, in women with dense breasts, subsequent-round AB-MR for supplemental screening achieved lower AIR versus baseline rounds (7.8% vs. 17.4%, p <.001), while maintaining high CDR (12.1 vs. 18.9 per 1000, p =.37). All cancers diagnosed by subsequent round AB-MR were stage 0 or 1; had size of 0.3-1.2 cm; and exhibited node-negative status.

For more information: www.arrs.org


Related Content

News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Breast Imaging

March 04, 2025 — Optellum has entered a strategic agreement with Volpara Health, a Lunit company and a provider of ...

Time March 04, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Oncology Related Products

Nov. 25, 2024 — CancerIQ has launched a new patient acquisition solution for imaging and oncology, CancerIQ Reach.The ...

Time December 03, 2024
arrow
News | Breast Imaging

Nov. 13, 2024 — Densitas has launched intelliRisk, its new high-risk breast cancer patient management platform ...

Time December 02, 2024
arrow
News | Mammography

Sept. 30, 2024 — Siemens Healthineers recently announced the Food and Drug Administration’s premarket approval (PMA) for ...

Time September 30, 2024
arrow
Subscribe Now